Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034965 | 1.00 | HTR2C (0.53) | HTR2CHRH4PDE5APDE2AHTR3A | |
| SCHEMBL30033897 | 0.92 | HTR2C (0.53) | HTR2CHRH4PDE2AHRH1BCDIN3D | |
| SCHEMBL23579785 | 0.92 | HTR2C (0.53) | HTR2CHRH4PDE2AHRH1BCDIN3D | |
| SCHEMBL23598905 | 0.90 | HTR2C (0.54) | HTR2CPDE5APDE2ABCDIN3D | |
| SCHEMBL30034770 | 0.90 | HTR2C (0.54) | HTR2CPDE5APDE2ABCDIN3D | |
| SCHEMBL13947132 | 0.86 | HTR2C (0.59) | HTR2CHRH4PDE5APDE2AHTR3A | |
| SCHEMBL13944729 | 0.85 | HTR2C (0.72) | HTR2CHRH4PDE5APDE2A | |
| SCHEMBL13946820 | 0.84 | HTR2C (0.70) | HTR2CHRH4PDE5APDE2AHTR3A | |
| SCHEMBL13944362 | 0.83 | HRH4 (0.63) | HTR2CHRH4PDE5APDE2AHRH1 | |
| SCHEMBL23579698 | 0.82 | PDE2A (0.55) | HTR2CPDE2ABCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | HTR2C 4192/4885HRH4 4647/4885PDE5A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.